Valuation: Unicycive Therapeutics, Inc.

Market Cap 135M 119M 111M 102M 191M 12.93B 194M 1.31B 514M 6.41B 508M 497M 22.15B P/E 2026 *
-3.49x
P/E 2027 * 0.96x
Enterprise Value 135M 119M 111M 102M 191M 12.93B 194M 1.31B 514M 6.41B 508M 497M 22.15B EV / Sales 2026 *
35.6x
EV / Sales 2027 * 0.47x
Free-Float
97.64%
Yield 2026 *
-
Yield 2027 * 46.6%
1 day-3.70%
1 week-13.18%
Current month+5.33%
1 month-30.72%
3 months-31.10%
6 months-29.63%
Current year-14.38%
1 week 4.87
Extreme 4.87
5.61
1 month 3.93
Extreme 3.93
5.93
Current year 3.93
Extreme 3.93
8.74
1 year 3.71
Extreme 3.71
8.74
3 years 2.02
Extreme 2.02
18.18
5 years 2.02
Extreme 2.02
33.8
10 years 2.02
Extreme 2.02
87.3
Manager TitleAgeSince
Chief Executive Officer 53 18/08/2016
Director of Finance/CFO 64 01/03/2021
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Chairman 53 18/08/2016
Director/Board Member 58 01/01/2018
Director/Board Member 58 06/09/2023
Date Insider Type Main position Quantity % Market Cap.
14/05/26 Free

Director

126,300 0.5004%
14/05/26 Free

Chief Executive Officer

762,200 3.0201%
14/05/26 Free

Executive/Senior Manager

169,500 0.6716%
Change 5-day change 1-year change 3-year change Capi.($)
-3.70%-13.18%+4.88%-57.43% 141M
-2.25%+1.55%+50.84%+70.04% 56.19B
-1.32%-2.71%+34.27%+77.57% 54.83B
+1.49%+0.13%-18.03%-13.94% 23.04B
-0.57%-4.13%+2.34%+387.73% 22.7B
-0.21%-0.62%+20.56%-10.90% 20.23B
0.00%+3.00%+27.41%-29.52% 17.83B
-0.97%-0.59%+33.12%+550.67% 15.65B
-6.69%-5.11%+169.13%+304.89% 15.24B
+1.25%+0.69%+27.30%+184.69% 14.03B
Average -1.30%-0.74%+35.18%+146.38% 23.99B
Weighted average by Cap. -1.17%-0.22%+36.51%+132.44%

Financials

2026 *2027 *
Net sales 3.8M 3.34M 3.11M 2.86M 5.36M 363M 5.45M 36.89M 14.44M 180M 14.28M 13.97M 623M 288M 253M 236M 217M 406M 27.55B 413M 2.8B 1.09B 13.66B 1.08B 1.06B 47.21B
Net income -40.34M -35.4M -32.96M -30.32M -56.84M -3.85B -57.81M -391M -153M -1.91B -151M -148M -6.6B 186M 163M 152M 140M 262M 17.79B 267M 1.81B 707M 8.82B 699M 684M 30.48B
Net Debt - -
Logo Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Employees
22
Date Price Change Volume
28/07/26 $4.940 -3.70% 1,007,223
27/07/26 $5.130 -5.00% 632,539
24/07/26 $5.400 -1.10% 497,709
23/07/26 $5.460 -1.97% 649,585
22/07/26 $5.570 -2.11% 595,078
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
4.940USD
Average target price
38.59USD
Spread / Average Target
+681.17%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. UNCY Stock